|
Daily Medical Update
Hypercalcemia
Monday, July 27, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Head & neck (2026) - Systematic Review
Key Findings
- Across nine studies including 2750 patients, preoperative vitamin D supplementation reduced postoperative hypocalcemia compared with no supplementation (RR 0.35, 95% CI 0.18-0.66).
- Supplementation also lowered symptomatic hypocalcemia (RR 0.53, 95% CI 0.29-1.00) and shortened length of stay by about half a day (MD -0.51 days, 95% CI -0.55 to -0.46).
📋 Practice Implication: Check and replete vitamin D before parathyroidectomy in primary hyperparathyroidism to reduce early postoperative calcium complications.
|
The Journal of clinical endocrinology and metabolism (2025) - Systematic Review
Key Findings
- In 13 studies with 915 patients, less-than-subtotal parathyroidectomy had higher recurrence than subtotal parathyroidectomy (RR 1.26, 95% CI 1.16-1.36) and total parathyroidectomy with autotransplantation (RR 1.35, 95% CI 1.22-1.49).
- Less-than-subtotal surgery had lower hypoparathyroidism than subtotal surgery (RR 0.90, 95% CI 0.82-0.98) and total parathyroidectomy with autotransplantation (RR 0.76, 95% CI 0.63-0.90).
📋 Practice Implication: For MEN1-related primary hyperparathyroidism, tailor surgical extent around the patient's tolerance for recurrence risk versus permanent hypoparathyroidism.
|
Echocardiography (Mount Kisco, N.Y.) (2026) - Systematic Review
Key Findings
- Among 24 studies including 881 patients, left ventricular ejection fraction did not significantly change after parathyroidectomy (SMD 0.15, 95% CI -0.12 to 0.49).
- Global longitudinal strain improved significantly after surgery (SMD 0.60, 95% CI 0.37 to 0.83), while E/A ratio reduction and increased left ventricular mass suggested ongoing remodeling.
📋 Practice Implication: When assessing cardiovascular response after parathyroidectomy, consider strain-based echocardiographic measures rather than relying only on ejection fraction.
|
American journal of nephrology (2025) - Randomized Controlled Trial
Key Findings
- Extended-release calcifediol increased mean total 25-hydroxyvitamin D from 24.1 to 157.7 ng/mL by 12 weeks, while placebo levels declined from 36.0 to 30.6 ng/mL.
- Mean 1,25-dihydroxyvitamin D normalized in 93% of treated participants, iPTH stabilized with extended-release calcifediol but rose 19.8% with placebo, and no hypercalcemia episodes were observed.
📋 Practice Implication: Extended-release calcifediol may help stabilize secondary hyperparathyroidism in hemodialysis patients, but its pilot scale warrants cautious adoption with close calcium and phosphorus monitoring.
|
International urology and nephrology (2025) - Randomized Controlled Trial
Key Findings
- In 72 randomized children with chronic kidney disease, proteinuria fell by a median 1.05 g/day with calcitriol plus enalapril versus 0.49 g/day with enalapril alone, a nonsignificant difference (P = 0.54).
- Percentage proteinuria reduction was 60.4% with combination therapy and 50.1% with enalapril alone (P = 0.48), and hypercalcemia was not observed during treatment.
📋 Practice Implication: Do not add calcitriol solely to improve pediatric CKD proteinuria outside selected indications, but its short-term calcium safety in this trial is reassuring.
|
|
💡
Summary
Recent hypercalcemia-related evidence emphasizes perioperative risk reduction and individualized parathyroid surgery, with several analyses focused on primary hyperparathyroidism and MEN1-associated disease. The strongest actionable findings support preoperative vitamin D repletion before parathyroidectomy, careful balancing of recurrence versus hypoparathyroidism in MEN1 surgery, and monitoring vitamin D analog strategies in kidney disease for calcium safety.
|
|